Aligos Therapeutics
Biopharma, Biotechnology, Health Care · 82 employees
Aligos is a biopharmaceutical company developing targeted therapeutics to address unmet medical needs in liver and viral diseases including MASH, CHB and COVID-19.
Funding history
- Funding Round — $105.0M — Feb 2025
- Funding Round — $92.2M — Nov 2023
- Funding Round — $85.0M — Jan 2020
Recent signals
- Apr 14, 2026: SEC 8-K (8.01): On April 14, 2026, Aligos Therapeutics, Inc. announced through a press release the first interim analysis results of the Phase 2 B-SUPREME study for veselifoscorvir sodium in patients with chronic hepatitis B virus (HBV) infection. The independent Data Safety Monitoring Review Board recommended continuing the study with an increased sample size to optimize statistical power, indicating that the futility criteria for the cohort were not met. Furthermore, the U.S. FDA granted Fast Track Designation to vesefoscorvir sodium, marking it as a potential best/first-in-class capsid assembly modulator for HBV treatment. This designation is expected to expedite the drug's development process and potential market introduction.
- Feb 28, 2025: Raised $105.0M
- Feb 12, 2025: Aligos Therapeutics Announces $105 Million Private Placement Financing to Fund Clinical Study
- Feb 13, 2024: Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
- Nov 07, 2023: Raised $92.2M
- Jan 16, 2020: Raised $85.0M
See plans & pricing → Track Aligos Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.